Why Corpay Is Still a Buy Despite JPMorgan's $350 Target

JPMorgan lowered the target, but not the rating

The market saw $400 to $350 and treated it like a verdict. JPMorgan cut the target, but it kept an Overweight rating on Corpay. That usually says more about a valuation reset than a drop in confidence in the business itself.

Other firms also trimmed targets around the same period, including Keefe, Bruyette & Woods, Raymond James, and UBS, according to GuruFocus. That kind of group reset can make a stock look weaker than it is when the underlying operating trend is still healthy.

Corpay's recent quarter still shows strong operating momentum

The clearest counterpoint is the latest quarter. Corpay delivered 25% revenue growth, 11% organic revenue growth for the fourth straight quarter, 44% growth in net income, and 49% growth in net income per diluted share. That is not the profile of a business losing speed.

The stock action also tells a mixed story. After a 12.51% earnings-day jump, the shares remained close to their 52-week high. That suggests investors were reacting more to the headline around the lower target than to any obvious deterioration in the business.